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doi:10.1016/j.fjs.2011.08.003Summary We report a successfully managed case of locally far-advanced hepatocellular
carcinoma (HCC) by preoperative downsizing by transarterial chemoembolization (TACE) and
three-dimensional conformal radiation therapy (3D-CRT), with subsequent surgical resection.
A 35-year-old man was referred to our hospital with right huge HCC in May, 2006. The labora-
tory data were normal except for elevated aspartate transaminase 100 U/L (0e38), alanine
transaminase 54 U/L(0e44), and a-fetoprotein 32 ng/mL(1e8). A computed tomography scan
of the liver revealed a 20-cm right side huge HCC with inferior vena cava tumor thrombus
(IVC-TT) and a second 2-cm HCC in segment III. TACE was performed on the right HCC with
20 mg of doxorubicin (Adriamycin), mixed with 10 mL of lipiodol and gelfoam. 3D-CRT was fol-
lowed by 60 Gy (3 Gy/fraction) over 4 weeks. The posttreatment computed tomography scan
showed significant shrinkage of the right tumor and IVC-TT. The tumors with the concomitant
IVC-TT were surgically removed 6 weeks later.
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of the celiac trunk showed a huge hypervascular stain inMedical history data obtained from patients with hepato-
cellular carcinoma (HCC) and major vascular invasion
reveal a median survival time of 9e12 weeks.1 The optimal
treatment for patients with HCC and major vascular inva-
sion remains controversial. We report a successfully
managed case of far-advanced HCC by preoperative trans-
arterial chemoembolization (TACE), three-dimensional
conformal radiation therapy (3D-CRT), and then surgical
resection.
2. Case report
A 35-year-old man complaining of right upper abdominal
pain visited a neighboring hospital, and was diagnosed to
have a single right-sided huge HCC. He was a chronic
hepatitis B carrier. He was then referred to our hospital for
further treatment in May, 2006. Physical examination
revealed a nontender, firm hepatomegaly, palpable 2 cm
below the costal margin. Laboratory data consisted of
a total bilirubin of 0.69 mg/dL (0e1.3); aspartate trans-
aminase, 100 U/L (0e38); alanine transaminase, 60 U/L
(0e44); albumin, 3.9 g/dL (3.5-5.0); international normal-
ized ratio, 1.02; and a-fetoprotein, 32 ng/mL (1e8). The
indocyanine green 15-minute retention test was 4.2%. The
patient’s Eastern Cooperative Oncology Group perfor-
mance status was 1. A triphasic computed tomography
(CT) scan showed a 20-cm HCC occupying the entire right
lobe with a tumor thrombus extending into the right
hepatic vein and the inferior vena cava and a second 2-cm
HCC in segment III (Figure 1). Surgery was considered
infeasible because of the inadequate estimated remnantFigure 1 Pretreatment liver CT. (A) The arterial phase showed a
delayed phase showed a tumor thrombus in the inferior vena cava
phase showed the longest axis of right lobe HCC about 20 cm in di
CT Z computed tomography; HCC Z hepatocellular carcinoma.liver volume (<40% of standard liver volume). Angiography
the right lobe, compatible with HCC, and tumor invasion
into the right hepatic vein. Hence TACE was performed on
the right HCC with 20 mg of doxorubicin (Adriamycin),
mixed with 10 mL of lipiodol and gelfoam. Subsequently
both the main tumor and the inferior vena cava tumor
thrombus (IVC-TT) were targeted by 3D-CRT (Elekta
Precise SLi, Crawley, United Kingdom) 2 weeks after TACE.
The daily fraction size was 3.0 Gy, given 5 days per week
for 4 weeks, to a cumulative dose of 60 Gy (Figure 2). A
triphasic CT scan 3 weeks after 3D-CRT showed shrinkage
of the main tumor from 20 cm to 14 cm in diameter. The
IVC-TT also shrank significantly (Figure 3). Six weeks after
3D-CRT, the patient underwent an extended right hepa-
tectomy with partial diaphragm resection by the anterior
approach, an inferior vena cava thrombectomy via the
right hepatic vein and a left partial hepatectomy
(Figure 4). Hepatic parenchymal transection was per-
formed with a Cavitron ultrasonic aspirator and bipolar
electrocautery under intermittent inflow control using the
Pringle maneuver (15-minute occlusion and 5-minute
declamping). The transection time was 140 minutes and
the operative blood loss was 400 mL. He did not receive any
blood transfusion perioperatively. Two weeks after surgery,
the patient was discharged without any complications.
From the macroscopic findings of the resected specimen,
the right hepatic vein was filled with a tumor thrombus.
Histologically, necrosis was recognized in 95% of the main
tumor, in 30% of the left tumor and in 100% of the IVC-TT.
The juxta-inferior vena cava hepatic veins were not
invaded by any malignant cells and the resection margins
were clear. The patient died of leukemia 3 years after the
operation.huge right lobe HCC and a small left lobe HCC (arrow); (B) the
(arrow); (C) reconstructed coronal view of the portal venous
ameter, and tumor thrombus in the right hepatic vein (arrow).
Figure 2 Isodose distribution of HCC conformal radio-
therapy, with prescription dose of 60 Gy. Red line: clinical
target volume of HCC. Pink line: 60 Gy isodose curve. Green
line: 56.84 isodose curve. Blue line: 44.21 Gy isodose curve.
Treatment machine: Elekta Precise SLi. HCC Z hepatocellular
carcinoma.
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Vascular invasion is a critical prognostic factor for patients
with HCC.2 Previous articles from the literature have
reported that the median survival time of patients with
major vascular invasion is 9e12 weeks if left untreated.1 To
improve the dismal prognosis, various treatments have
been applied to patients with advanced HCC. Pawlik and
colleagues3 reported results from a multicenter study
which suggested that patients with HCC and major vascular
invasion derived survival benefit from surgical resection,
with an overall 5-year survival rate of 10%.
TACE has been shown to improve survival compared with
supportive care in recent meta-analyses.4 Although TACE
has been frequently used in the treatment of unresectable
HCC, its limitations are also well known, especially in large
tumors. Previous studies have suggested a benefit of
combining radiation therapy (RT) and TACE in patients with
advanced HCC.5Figure 3 Posttreatment liver triphasic CT. (A) The delayed phas
enlarged segment III HCC from 2 cm to 3 cm; (B) the delayed pha
residual tumor thrombus (arrow). CT Z computed tomography; HCHistorically, RT has played a minor role in the manage-
ment of patients with unresectable liver cancer, primarily
because of the low tolerance of the whole liver to RT.
However, recent advances have allowed the safe delivery
of higher dose external beam RT to liver tumors, such as
advanced imaging to improve tumor definition, three-
dimensional radiation planning techniques to deliver high
doses that conform tightly to the tumor, image-guided
radiotherapy to localize the tumor at the time of treat-
ment, tumor immobilization and organ tracking to account
for organ motion due to breathing, and improved knowl-
edge of the partial volume tolerance of the liver to radia-
tion. These advances have revived RT as an additional
treatment option in primary liver malignancies.6
The resected specimen in our case showed 95% necrosis
in the main tumor while the left sided tumor, which did
not receive any downsizing treatment, only showed 30%
tumor necrosis attributed to the natural tumor biology.
The fact that the main tumor received both TACE and RT
makes the causative factor for tumor shrinkage and
necrosis difficult. However, the IVC-TT showed 100%
necrosis with significant shrinkage after RT. Furthermore,
microscopic examination of the irradiated non-tumor liver
tissue showed sinusoidal lining cell injury causing so-called
veno-occlusive disease7 in the microcirculation. This effect
might block tumor angiogenesis and be responsible for
tumor shrinkage. These facts have led us to believe that
RT was the main causative factor for downsizing and tumor
necrosis.
The anterior approach is the preferred technique for
extended right-sided hepatic resection for large HCC.8 This
is because of the challenging right side liver mobilization
with an increased risk of tumor rupture and higher blood
loss associated with the classic approach. Our blood loss
was limited to 400 mL with no need for transfusion because
of this approach. Furthermore, we resected a part of the
right diaphragm to limit the risk for tumor spillage and
blood loss.
The patient died of leukemia 3 years postoperatively.
Whether this was linked to RT remains controversial but
secondary cancers induced by RT have become a clinically
significant issue.9 This increase in risk has to be balancede showed shrinkage of right lobe HCC from 20 cm to 14 cm but
se image at confluence of the hepatic veins showed a minimal
C Z hepatocellular carcinoma.
Figure 4 (A) There were diffuse black spots on the irradiated right lobe liver; (B) anterior approach extended right hepatectomy
was performed. The inferior vena cava tumor thrombus (arrow) was removed via the right hepatic vein; (C) the tumor in segment III
was removed by a left partial hepatectomy; (D) the right tumor was 14 cm in diameter and macroscopically almost necrotic.
Downsizing by 3D-CRT & TACE on HCC 159against the generally high spontaneous cancer risk in these
individuals and the benefits accruing from radiotherapy.
It is concluded that preoperative treatment with 3D-CRT
combined with TACE has a potential role in downsizing large
HCC with induced tumor necrosis, thereby facilitating
radical resection without additional surgical risks.References
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